MBHB Partner Kevin Noonan on biologics, biosimilars and patent law complexities

The role some pharmaceutical companies play in developing both biologics and biosimilars complicates their IP law strategies. MBHB Partner Kevin Noonan offers insight in Bloomberg Law. View the article.